(S)-3-(4-isobutylphenyl)butan-2-one | 709039-99-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (S)-3-(4-isobutylphenyl)butan-2-one
• 英文别名: (3S)-3-[4-(2-methylpropyl)phenyl]butan-2-one
• CAS: 709039-99-6
• 化学式: C₁₄H₂₀O
• 分子量: 204.312
• InChiKey: VOYZJYGIHFRNAG-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] HYDROGELATORS COMPRISING D-AMINO ACIDS<br/>[FR] COMPOSÉS FORMANT DES HYDROGELS COMPRENANT DES ACIDES AMINÉS D
  申请人：UNIV BRANDEIS

  公开号：WO2014074789A1

  公开（公告）日：2014-05-15

  Described herein are compounds comprising an oligopeptide and a non-steroidal antiinflammatory agent. The compounds self-assemble into supramolecular hydrogels and can be used as topical treatments for inflammatory conditions, such as osteoarthritis. Also described herein are oligopeptides compounds made from D-amino acid residues that form supramolecular hydrogels. The compounds may be functionalized with active agents, such as anticancer therapeutic agents, antiinflammatory agents, or imaging agents, therefore providing new mechanisms for delivery of active agents.

  本文描述了包含寡肽和非甾体抗炎药物的化合物。这些化合物自组装成超分子水凝胶，可用作治疗炎症病症，如骨关节炎的局部治疗。本文还描述了由D-氨基酸残基制成的寡肽化合物，形成超分子水凝胶。这些化合物可以与活性剂（如抗癌治疗剂、抗炎药物或成像剂）功能化，从而提供了传递活性剂的新机制。
• [EN] CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES<br/>[FR] ARYLCETONES CHIRALES UTILISEES POUR TRAITER DES MALADIES INFLAMMATOIRES DEPENDANT DES NEUTROPHILES
  申请人：DOMPE SPA

  公开号：WO2004052830A1

  公开（公告）日：2004-06-24

  ABSTRACT The compounds of formula (I): where Ar is an aromatic ring and Ra, Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, such as psoriasis, rheumatoid arthritis, ulcerative cholitis and for the treatment of damages caused by ischemia and reperfusion.

  摘要 公式(I)的化合物：其中Ar是芳香环，Ra，Rb如描述中所定义，可用作治疗药物，用于治疗由IL-8诱导的中性粒细胞浸润介导的疾病，如牛皮癣、类风湿关节炎、溃疡性结肠炎以及用于治疗缺血再灌注引起的损伤。
• Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders
  申请人：Laria Julio Cesar Castro Palomino

  公开号：US20150025006A1

  公开（公告）日：2015-01-22

  One aspect of the present invention is a pharmaceutical combination comprising (a) an anti-inflammatory agent/anti-oxidant agent conjugate; and (b) an insulin secretogogue, an insulin sensitizer, an alpha-glucosidase inhibitor, a peptide analog, or a combination thereof. Another aspect of the invention relates to methods of treating metabolic disorders with such conjugates.

  本发明的一个方面是一种药物组合，包括（a）一种抗炎/抗氧化药物偶联物；以及（b）一种胰岛素分泌素、胰岛素敏感剂、α-葡萄糖苷酶抑制剂、肽类类似物或其组合。本发明的另一个方面涉及使用这种偶联物治疗代谢性疾病的方法。
• Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases
  申请人：Allegretti Marcello

  公开号：US20060247297A1

  公开（公告）日：2006-11-02

  The compounds of formula (I): where Ar is an aromatic ring and Ra, Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, such as psoriasis, rheumatoid arthritis, ulcerative cholitis and for the treatment of damages caused by ischemia and reperfusion.

  化合物的公式（I）：其中Ar是芳香环，Ra，Rb如描述中定义的那样，可用作治疗剂，用于治疗由IL-8诱导的中性粒细胞浸润介导的疾病，如牛皮癣，类风湿性关节炎，溃疡性结肠炎，并用于治疗缺血再灌注所致的损伤。
• MODIFIED iRNA AGENTS
  申请人：MANOHARAN Muthiah

  公开号：US20100076056A1

  公开（公告）日：2010-03-25

  The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. The tether in turn can be connected to a selected moiety, e.g., a ligand, e.g., a targeting or delivery moiety, or a moiety which alters a physical property. The cleavable linking group is one which is sufficiently stable outside the cell such that it allows targeting of a therapeutically beneficial amount of an iRNA agent (e.g., a single stranded or double stranded iRNA agent), coupled by way of the cleavable linking group to a targeting agent—to targets cells, but which upon entry into a target cell is cleaved to release the iRNA agent from the targeting agent. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

  本发明涉及iRNA剂，其中最好包括一个单体，其中核糖基团已被替换为除核糖以外的基团，并进一步包括一个具有一个或多个连接基团的连接件，其中至少一个连接基团是可切断的连接基团。连接件反过来可以连接到所选的基团，例如，配体，例如，靶向或传递基团，或改变物理性质的基团。可切断的连接基团是足够稳定的连接基团，以便在细胞外定向治疗有益量的iRNA剂（例如，单链或双链iRNA剂），通过可切断的连接基团与靶向剂结合，以靶向细胞，但在进入靶细胞后被切断以释放iRNA剂从靶向剂中。包括这样一个单体可以允许调节iRNA剂的一个性质，将其纳入其中，例如，通过使用非核糖基团作为配体或其他实体（例如，亲脂性基团，例如，胆固醇）的连接点，直接或间接地连接。本发明还涉及制备和使用这种修改的iRNA剂的方法。